These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7488317)

  • 1. Ex vivo anti-platelet effects of isocarbacyclin methyl ester incorporated in lipid microspheres in rabbits.
    Inoue K; Aoki Y; Hayashi M; Kitahara S; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):980-4. PubMed ID: 7488317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-platelet effects of isocarbacyclin methyl ester on human and rabbit platelets in vitro.
    Inoue K; Aoki Y; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):975-9. PubMed ID: 7488316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isocarbacyclin methyl ester incorporated into lipid microspheres on cutaneous blood flow in rat.
    Sawada K; Taneda K; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):988-90. PubMed ID: 7488319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
    Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exhibition of anti-platelet effect of isocarbacyclin methyl ester and its free acid via an increase in cAMP in platelets.
    Aoki Y; Inoue K; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):970-4. PubMed ID: 7488315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasorelaxant effect of isocarbacyclin methyl ester incorporated into lipid microspheres on isolated canine arteries.
    Sawada K; Aoki K; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):985-8. PubMed ID: 7488318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease.
    Murakami T; Sawada K; Taneda K; Hayashi M; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):991-4. PubMed ID: 7488320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
    Michel G; Seipp U
    Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.
    Uemura T; Takamatsu H; Kawasaki T; Taniguchi M; Yamamoto E; Tomura Y; Uchida W; Miyata K
    Eur J Pharmacol; 2006 Apr; 536(1-2):154-61. PubMed ID: 16566917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K; Cissé-Thiam M; Drouet L
    Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of prostacyclin in rabbits: elimination kinetics and blood pressure response.
    Skrinska VA; Lucas FV; Chisolm GM; Hesse BL
    J Lab Clin Med; 1986 Mar; 107(3):187-93. PubMed ID: 3512745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the isocarbacyclin methyl ester clinprost incorporated into lipid microspheres, in focal ischemia of stroke-prone spontaneously hypertensive rats.
    Yae T; Araki H; O-ogami Y; Iwasaki K; Tanabe H; Fujiwara M
    Arzneimittelforschung; 1997 Nov; 47(11):1200-3. PubMed ID: 9428973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Platelet aggregation during hypotensive anesthesia using prostaglandin E1].
    Tanaka M; Hosokawa T; Tanaka Y; Miyazaki M
    Masui; 1991 Nov; 40(11):1636-40. PubMed ID: 1766114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I; Morise T; Yasuhara S; Takeda Y; Koshida H; Takeda R
    Br J Clin Pharmacol; 1985 Dec; 20(6):681-3. PubMed ID: 3912001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
    Sim AK; McCraw AP; Cleland ME; Nishio S; Umetsu T
    Arzneimittelforschung; 1985; 35(12):1816-8. PubMed ID: 3913423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
    Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
    Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
    Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.